MedTrace Logo

Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock

NCT00604019 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2023-01-11

Study results available
· View outcomes & findings →

Summary

We are performing a prospective, randomized, controlled trial of dopamine versus norepinephrine for septic shock. The trial will enroll patients with suspected or documented site of infection and having 2 out of the three SIRS criteria. Patients will also be receiving standard of care, early-goal directed therapy including but not limited to fluid resuscitation, appropriate and early antibiotics, source control and evaluation for drotrecogin alpha where deemed appropriate, while being supported for septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Dopamine

Dopamine 5-20 mcg/kg/min to pre-determined max of 20

DRUG

Norepinephrine

Norepinephrine 5-20 mcg/min, to a pre-determined max of 20

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Robert A Balk, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604019 on ClinicalTrials.gov